Reumatizam, Vol. 52 No. 2, 2005.
Conference paper
Raloxifene (Evista®) in the treatment of postmenopausal osteoporosis - the profile of the patient
Darko Kaštelan
; Department for Endocrinology, Clinic for Internal Medicine, Clinical Hospital Centre Zagreb, Zagreb, Croatia
Mirko Koršić
; Department for Endocrinology, Clinic for Internal Medicine, Clinical Hospital Centre Zagreb, Zagreb, Croatia
Abstract
Osteoporosis, breast cancer and cardiovascular diseases are major health problems among postmenopausal women. Several pharmacologic options for treatment of osteoporosis are available, including hormone replacement therapy (HRT), bisphosphonates, calcitonin and selective estrogen receptor modulators. However, long-term HRT is associated with unwanted side effects such as vaginal bleeding and breast cancer and bisphosphonates, besides bone, have no other benefits. Therefore, raloxifene, the first of the second-generation of SERMs represents a significant improvement in the treatment of postmenopausal women. It could have either estrogen agonist (bone) or antagonist (breast) activity according to the type of estrogen-responsive tissue. Raloxifene prevents bone loss, reduces the number of vertebral fractures in women with and without prevalent vertebral fractures, induces reduction of estrogen-receptor positive invasive breast cancer and has potential beneficial effect on cardiovascular diseases in women with high risk. CORE study, that was recently published, confirmed previously observed reduction of invasive breast cancer in women treated with raloxifene (MORE study), while the data on skeletal effects after 8-years treatment with raloxifene will be published in the near future. Further studies (RUTH, STAR) will provide additional information on efficacy and safety of raloxifene.
Keywords
osteoporosis; SERM; raloxifene; fracture; breast cancer; cardiovascular disease
Hrčak ID:
125923
URI
Publication date:
14.10.2005.
Visits: 1.369 *